Safety Concerns with Breakthrough Cancer Pain Treatments


Like many analgesics, transmucosal immediate-release fentanyl (TIRF) products can be associated with adverse events. Concerns over these unintended consequences are often enhanced when treating breakthrough cancer pain, since patients with cancer can be frail and often elderly, according to Vitaly Gordin, MD.

For patients taking TIRF products, the main concerns are excessive sedation with respiratory suppression and constipation. Additionally, patients may be unstable when taking analgesics, resulting in falls and fractures. These concerns should be weighed when determining the appropriate dose, Gordin notes.

In general, TIRF products should be stored in a lock box and kept away from children and pets, according to Jeri L. Ashley, RN. Additionally, patients should avoid driving while using analgesics.

Related Videos
Getting Black Men Involved in Their Health Care, Clinical Research
Patient Involvement in Advanced HF Treatment, with Ashley Malliett, DMSc, MPAS, PA-C
Aaron Henry, PA-C, MSHS: Regaining Black Male Patient Trust in the Doctor's Office
Tailoring Chest Pain Diagnostics to Patients, with Kyle Fortman, PA-C, MBA
Solutions to Prevent Climate Change-Related Illness, with Janelle Bludhorn, PA-C
Kyle Fortman, PA-C, MBA: Troponin and Heart Injury Risk Screening Recommendations
What Should the American Academy of Physician Associates Focus on in 2025?
The Rising Rate of Heat-Related Illness, with Janelle Bludhorn, PA-C
Danielle O'Laughlin, PA-C, MS: Navigating Long-Term Risks, Family Planning in PCOS
© 2024 MJH Life Sciences

All rights reserved.